Nuveen NASDAQ 100 Dynamic Overw
QQQX NASDAQNuveen NASDAQ 100 Dynamic Overw looks about 74% undervalued against its cash-flow value. Its growth outlook scores strong.
At a glance
tap a tile to dig inOtto's verdict
the tiles above, in a line each- Value Looks ~74% undervalued against Otto's cash-flow estimate.
- Health 9 of 9 health checks pass.
- Street Analysts lean none.
- Dividend Pays a dividend — yields 9.67%.
- Insiders Insiders, last 12 months: 1 buys · 1 sells.
Not investment advice — Otto just crunches numbers.
Price trend
+669.1% over all saved history · S&P 500 +430.8%
What think
The market's move: +669.1% over the past year
Trading 79% up its 52-week range. Price is the market's live vote — not advice.
No analyst consensus is available for QQQX.
Insiders: 1 buy · 1 sale in recent filings
Open-market trades from SEC Form 4. Sales are often pre-planned (10b5-1); buys tend to say more. Sentiment, not advice.
InvestRight readers: 0 watching
This site's own activity — not a broad measure. Sentiment, not advice.
The snowflake
checks passed on each axis- Value 2/2 checks
- Future 2/2 checks
- Past 2/2 checks
- Health 0/— checks
- Dividend 3/3 checks
What does this show?
Five quick health scores — Value, Future, Past, Health and Dividend — each 0–100%. A bigger, more even shape means a stock that scores well across the board; a spiky one is strong on some axes and weak on others.
Learn more on Investopedia →Fair value
our estimate · not analyst forecast74% below our estimate — you'd be paying less than our numbers say it's worth.
How we got there
A 2-stage discounted-cash-flow on owner earnings (net income): grow it at the capped historical trend for five years, fade to a 2.5% long-run rate, discount everything at 9.0%. It's a transparent estimate from past numbers, not a licensed forecast — treat it as one lens, not truth.
What does this show?
Our estimate of what one share is worth based on the cash the business is expected to generate (a discounted-cash-flow model), next to today's price. Below fair value hints undervalued, above hints expensive — it's an estimate, not a guarantee.
Learn more on Investopedia →Health checks
9 checks run on free data- ✓ Trading below our fair-value estimate +74% vs our DCF estimate
- ✓ Earnings grew over the period -376.0M → 183.2M
- ✓ Earnings trending up latest above earliest
- ✓ Payout ratio under 75% payout 59.7% of earnings
- ✓ Revenue higher than five years ago -375.0M → 184.2M
- ✓ Return on equity improving ROE 12.1% vs -39.6% 3yr ago
Show all 9 checks by axis
Value 2/2 passed
- ✓ Trading below our fair-value estimate +74% vs our DCF estimate
- – P/B below industry industry P/B not on the free feed
- – P/E below industry industry P/E not on the free feed
- – P/E below peer average peer P/Es land after the next refresh
- – P/S sane vs its own history needs multi-year P/S (Tier B)
- ✓ More than 20% below fair value +74% margin of safety
Future 2/2 passed
- ✓ Earnings trending up latest above earliest
- – Growth beats the industry industry growth not on the free feed
- – Earnings growth beats the market
- – Revenue trending up
- ✓ Return on equity improving ROE 12.1% vs -39.6% 3yr ago
Past 2/2 passed
- ✓ Earnings grew over the period -376.0M → 183.2M
- – High-quality earnings (few one-offs) one-off detection deferred — needs statement detail
- – Growth accelerating vs its average n/a (loss years)
- ✓ Revenue higher than five years ago -375.0M → 184.2M
- – Return on equity above 20%
Health 0/— passed
- – Debt/equity falling over time n/a
- – Debt is under 40% of equity
- – Debt well covered by cash flow
- – Interest comfortably covered by profit
- – Short-term assets cover long-term debt n/a
- – Short-term assets cover short-term bills n/a
Dividend 3/3 passed
- – Dividend covered by earnings and cash flow n/a
- – Dividend growing over time n/a
- – No dividend cut in recent years n/a
- ✓ Payout ratio under 75% payout 59.7% of earnings
- ✓ Yield beats the market yield 9.67% vs market ~1.5%
- ✓ Yield in the top quartile of payers yield 9.67% vs 2.85% cut among the 56 payers Otto tracks
What does this show?
Pass/fail rules on the company's finances — debt levels, profitability, cash cover and so on. More greens means a sturdier balance sheet; an n/a just means we didn't have that data point.
Learn more on Investopedia →Past performance
recent history from Yahoo FinanceRevenue
Earnings
What does this show?
How revenue, earnings and free cash flow have grown over the years. Bars rising left-to-right show a growing business; the dashed line is a market-average pace for comparison.
Learn more on Investopedia →Dividend
from cash actually paid, not promisesWhat does this show?
The share of profit paid back to shareholders as cash. Yield is that cash as a % of the price; the payout gauge shows how much of earnings is paid out (over ~75% can be hard to sustain).
Learn more on Investopedia →Ownership & insiders
from SEC Form 4 filings1 open-market buy · 1 sale in the last 2 saved filings
- Buy Zimmerman Gifford R · Secretary 1,000 sh · $14,127 2020-11-10
- Sell Nuveen Fund Advisors, Llc 1 sh · $21 2017-04-13
Insiders must report within two business days. Sales are often pre-planned (10b5-1) rather than a signal — buys tend to say more.
What does this show?
Buys and sells by the company's own directors and officers, from their SEC filings. Insiders sell for many reasons, but clusters of open-market buying can signal confidence.
Learn more on Investopedia →Spot a missing competitor? Sign in to add it — it'll show for everyone.
What does this show?
A few peers in the same business, each with its own mini snowflake, so you can see how this company stacks up rather than judging it in isolation. Anyone signed in can add a missing competitor — it shows for everyone, marked as user-added.
Learn more on Investopedia →Leadership
Yahoo Finance · photos & bios via WikidataRanked by title — reporting lines aren't public data. Compensation is the total Yahoo reports; blank means it isn't disclosed there.
In the news
My notes
Sign in to keep a private decision journal on this stock — only you can see your notes.
Hi! I can explain Nuveen's numbers — valuation, health, the dividend, the fair-value gap. What would you like to know?
Otto explains what's on this page — not investment advice.